Blockchain Registration Transaction Record

Nutriband Announces 25% Preferred Stock Dividend Ahead of AVERSA Fentanyl FDA Approval

Nutriband Inc. announces a 25% preferred stock dividend linked to FDA approval of its AVERSA Fentanyl, showcasing commitment to shareholder value and innovation in abuse-deterrent technology.

This news is significant for investors and the pharmaceutical industry as it highlights Nutriband's innovative approach to preventing drug abuse through its AVERSA technology. The announcement of a preferred stock dividend reflects the company's confidence in its product pipeline and its commitment to shareholder value, marking a pivotal step towards the commercialization of a potentially life-saving technology. For stakeholders, this represents not just an investment opportunity but a chance to be part of a solution addressing the critical issue of drug abuse.